124 related articles for article (PubMed ID: 35007092)
1. Changes in pain during buprenorphine maintenance treatment among patients with opioid use disorder and chronic pain.
Edwards KA; Vowles KE; McHugh RK; Venner KL; Witkiewitz K
J Consult Clin Psychol; 2022 Apr; 90(4):314-325. PubMed ID: 35007092
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
[TBL] [Abstract][Full Text] [Related]
3. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
Worley MJ; Heinzerling KG; Shoptaw S; Ling W
Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
[TBL] [Abstract][Full Text] [Related]
4. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
Altice FL; Bruce RD; Lucas GM; Lum PJ; Korthuis PT; Flanigan TP; Cunningham CO; Sullivan LE; Vergara-Rodriguez P; Fiellin DA; Cajina A; Botsko M; Nandi V; Gourevitch MN; Finkelstein R;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S22-32. PubMed ID: 21317590
[TBL] [Abstract][Full Text] [Related]
5. Repeated measures analysis of opioid use disorder treatment on clinical opiate withdrawal scale in a randomized clinical trial: sex differences.
Wang K; Shafique S; Xiao D; Walter SM; Liu Y; Piamjariyakul U; Xie C
J Addict Dis; 2024; 42(1):33-44. PubMed ID: 36655851
[TBL] [Abstract][Full Text] [Related]
6. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.
Korthuis PT; Fiellin DA; Fu R; Lum PJ; Altice FL; Sohler N; Tozzi MJ; Asch SM; Botsko M; Fishl M; Flanigan TP; Boverman J; McCarty D;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S83-90. PubMed ID: 21317600
[TBL] [Abstract][Full Text] [Related]
7. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
[TBL] [Abstract][Full Text] [Related]
8. Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020.
Bach P; Bawa M; Grant C; Milloy MJ; Hayashi K
Int J Drug Policy; 2022 Mar; 101():103545. PubMed ID: 34875527
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine-naloxone Versus Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy.
Perry BN; Vais S; Boateng JO; Jain M; Wachman EM; Saia KA
J Addict Med; 2022 Nov-Dec 01; 16(6):e399-e404. PubMed ID: 35916423
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine Induction in Persons With Opioid Use Disorder Hospitalized with Acute Hepatitis A.
Oller DA; Thornton C; Nuzzo PA; Fanucchi LC
J Addict Med; 2021 May-Jun 01; 15(3):187-190. PubMed ID: 32909986
[TBL] [Abstract][Full Text] [Related]
11. Impact of Emergency Department-Initiated Buprenorphine on Repeat Emergency Department Utilization.
Skains RM; Reynolds L; Carlisle N; Heath S; Covington W; Hornbuckle K; Walter L
West J Emerg Med; 2023 Nov; 24(6):1010-1017. PubMed ID: 38165181
[TBL] [Abstract][Full Text] [Related]
12. Associations of Methadone and BUP/NX Dose Titration Patterns With Retention in Treatment and Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: Secondary Analysis of the OPTIMA Study.
Bakouni H; Haquet L; Socias ME; Le Foll B; Lim R; Ahamad K; Jutras-Aswad D;
J Addict Med; 2024 Mar-Apr 01; 18(2):167-173. PubMed ID: 38258865
[TBL] [Abstract][Full Text] [Related]
13. The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample.
Nielsen S; Hillhouse M; Weiss RD; Mooney L; Sharpe Potter J; Lee J; Gourevitch MN; Ling W
Am J Addict; 2014; 23(4):343-8. PubMed ID: 24112096
[TBL] [Abstract][Full Text] [Related]
14. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.
Rosenblum A; Cruciani RA; Strain EC; Cleland CM; Joseph H; Magura S; Marsch LA; McNicholas LF; Savage SR; Sundaram A; Portenoy RK
J Opioid Manag; 2012; 8(6):369-82. PubMed ID: 23264315
[TBL] [Abstract][Full Text] [Related]
15. Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics.
Korthuis PT; Tozzi MJ; Nandi V; Fiellin DA; Weiss L; Egan JE; Botsko M; Acosta A; Gourevitch MN; Hersh D; Hsu J; Boverman J; Altice FL;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S39-45. PubMed ID: 21317593
[TBL] [Abstract][Full Text] [Related]
16. Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation.
Randall A; Hull I; Martin SA
J Addict Med; 2023 Mar-Apr 01; 17(2):237-240. PubMed ID: 36149001
[TBL] [Abstract][Full Text] [Related]
17. Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.
Lucas GM; Young A; Donnell D; Richardson P; Aramrattana A; Shao Y; Ruan Y; Liu W; Fu L; Ma J; Celentano DD; Metzger D; Jackson JB; Burns D;
Drug Alcohol Depend; 2014 Sep; 142():139-45. PubMed ID: 24999060
[TBL] [Abstract][Full Text] [Related]
18. Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.
Bakouni H; Sharafi H; Drouin S; Fortin R; Marsan S; Brissette S; Socias ME; Le Foll B; Lim R; Jutras-Aswad D
Can J Psychiatry; 2024 Apr; 69(4):252-263. PubMed ID: 37899716
[TBL] [Abstract][Full Text] [Related]
19. Does the Addition of Naloxone in Buprenorphine/Naloxone Affect Retention in Treatment in Opioid Replacement Therapy?: A Systematic Review and Meta-Analysis.
Dalton K; Butt N
J Addict Nurs; 2019; 30(4):254-260. PubMed ID: 31800516
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial.
McAnulty C; Bastien G; Eugenia Socias M; Bruneau J; Foll BL; Lim R; Brissette S; Ledjiar O; Marsan S; Talbot A; Jutras-Aswad D;
Drug Alcohol Depend; 2022 Oct; 239():109604. PubMed ID: 36037586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
